```html

Infective Endocarditis – A Patient‑Friendly Guide

Overview

Infective endocarditis (IE) is an infection of the inner lining of the heart chambers and heart valves (the endocardium). Microorganisms—most commonly bacteria, but occasionally fungi—attach to damaged or abnormal heart tissue and form vegetations (clusters of organisms, fibrin, and platelets). These vegetations can break off and travel to other organs, causing serious complications.

Who it affects

• Adults aged 50–70 years are most commonly diagnosed, but IE can occur at any age.
• People with pre‑existing heart valve disease, prosthetic heart valves, or a history of prior endocarditis are at higher risk.
• Intravenous drug users (IVDU) represent a distinct demographic, often developing right‑sided endocarditis.
• Patients with certain congenital heart defects, cardiac implantable electronic devices (pacemakers, defibrillators), or recent invasive procedures (dental, GI, urologic) are also vulnerable.

Prevalence

• In the United States, the incidence is approximately 1–5 cases per 100,000 person‑years.<sup>1</sup>
• Globally, incidence ranges from 3 to 10 per 100,000 person‑years, with higher rates in low‑ and middle‑income countries due to limited access to preventive dental care and higher rheumatic heart disease prevalence.<sup>2</sup>
• Mortality remains high—30‑40 % in hospitalized cohorts, despite advances in antibiotics and surgery.<sup>3</sup>

Symptoms

Symptoms can develop quickly (acute IE) or insidiously over weeks to months (sub‑acute IE). Because the presentation varies, a high index of suspicion is crucial.

Common signs and symptoms

• Fever & chills – the most frequent symptom; often >38 °C (100.4 °F).
• Fatigue & weakness – generalized malaise, sometimes severe.
• Night sweats – soaking sweats, especially in sub‑acute disease.
• New or changing heart murmur – turbulence caused by vegetations or valve damage.
• Weight loss – unexplained, may be significant.

Peripheral manifestations

• Osler nodes – tender, erythematous nodules on fingertips or toes (immune complex phenomenon).
• Roth spots – retinal hemorrhages with pale centers, seen on eye exam.
• Janeway lesions – painless, erythematous macules on palms/soles, representing septic emboli.
• Splinter hemorrhages – tiny linear bleeds under the nail bed.

Systemic complications that may herald IE

• Heart failure – shortness of breath, orthopnea, peripheral edema.
• Stroke or transient ischemic attack – due to embolic vegetations reaching cerebral vessels.
• Renal dysfunction – hematuria, proteinuria, or acute kidney injury.
• Arthralgias or septic arthritis – joint pain, swelling.

Causes and Risk Factors

Microbial agents

• Staphylococcus aureus – most common cause of acute IE, especially in IVDU and healthcare‑associated infections.
• Viridans group streptococci – typical for sub‑acute IE after dental procedures.
• Enterococci (e.g., Enterococcus faecalis) – linked to genitourinary or gastrointestinal instrumentation.
• Coagulase‑negative staphylococci – frequent in prosthetic‑valve infections.
• Fungi (Candida, Aspergillus) – rare, usually in severely immunocompromised hosts.

Key risk factors

• Pre‑existing valve disease (rheumatic fever, mitral valve prolapse, bicuspid aortic valve).
• Prosthetic heart valves or cardiac devices.
• Intravenous drug use (introduces skin flora directly into bloodstream).
• Recent invasive procedures without adequate antibiotic prophylaxis (dental extraction, GI endoscopy, urologic surgery).
• Chronic indwelling catheters (central venous lines, hemodialysis catheters).
• Immunosuppression (HIV, chemotherapy, long‑term steroids).
• Congenital heart disease or prior history of endocarditis.

Diagnosis

Diagnosis combines clinical suspicion, microbiologic data, and imaging. The widely used Duke Criteria (1994, updated 2000) categorizes cases as “definite,” “possible,” or “rejected.”

Laboratory tests

• Multiple blood cultures – at least three sets drawn from separate sites before antibiotics; yields organism in ≥90 % of cases.
• Complete blood count (CBC) – often shows anemia of chronic disease, leukocytosis.
• Inflammatory markers – elevated ESR and C‑reactive protein (CRP).
• Serologic tests – for fastidious organisms (e.g., Coxiella burnetii, Bartonella spp.) when cultures are negative.
• Urinalysis – may reveal microscopic hematuria or proteinuria.

Imaging studies

• transthoracic echocardiography (TTE) – first‑line; detects vegetations >2‑3 mm in 70‑80 % of native‑valve IE.
• Transesophageal echocardiography (TEE) – superior (<90 % sensitivity) for prosthetic valves, intracardiac devices, or when TTE is inconclusive.
• CT or MRI of the brain – indicated if neurologic symptoms emerge; identifies embolic strokes.
• CT angiography or PET/CT – useful for detecting extracardiac septic emboli or prosthetic‑valve infection.

Applying the Duke Criteria (simplified)

Major	Minor
Positive blood cultures for typical organisms	Fever ≥38 °C
Evidence of endocardial involvement on echo (new vegetation, abscess)	Pre‑disposing heart condition or IVDU
	Vascular phenomena (Janeway lesions, emboli, mycotic aneurysm)
	Immunologic phenomena (Osler nodes, Roth spots, glomerulonephritis)

Definite IE = 2 major, or 1 major + 3 minor, or 5 minor criteria.

Treatment Options

Treatment is time‑sensitive and must be coordinated by an infectious‑disease specialist and cardiologist.

Antimicrobial therapy

• Empiric broad‑spectrum IV antibiotics are started after the first set of cultures (e.g., vancomycin + gentamicin + ceftriaxone) pending organism identification.
• Once the pathogen and sensitivities are known, therapy is narrowed—common regimens include:
  • Staphylococcus aureus – nafcillin or oxacillin (if MSSA) or vancomycin/daptomycin (if MRSA) for 4–6 weeks.
  • Viridans streptococci – penicillin G or ceftriaxone + gentamicin for 4 weeks.
  • Enterococci – ampicillin + ceftriaxone or ampicillin + gentamicin for 6 weeks.
  • Fungal IE – amphotericin B + flucytosine, often followed by lifelong oral azole suppression.
• Therapy typically lasts 4–6 weeks, administered intravenously in a hospital or via an outpatient parenteral antimicrobial therapy (OPAT) program.

Surgical interventions

Approximately 25‑50 % of patients with IE require cardiac surgery.

• Indications – heart failure due to valve dysfunction, uncontrolled infection (persistent bacteremia, abscess, fistula), large vegetations (>10 mm) that pose embolic risk, or prosthetic‑valve infection.
• Procedures include valve repair, valve replacement (mechanical or bioprosthetic), or removal of infected device leads.

Supportive & lifestyle measures

• Maintain adequate hydration and nutrition; malnutrition worsens outcomes.
• Control pain and fever with acetaminophen (avoid NSAIDs that may impair platelet function).
• Monitor for signs of bleeding if on anticoagulation (common in prosthetic‑valve patients).

Living with Infective Endocarditis

Recovery can be lengthy; the following tips help patients manage day‑to‑day life.

Medication adherence

• Set alarms or use a pill‑box for IV antibiotic dosing schedules.
• Never stop antibiotics early, even if you feel better.
• Report any side effects (e.g., rash, kidney dysfunction) promptly.

Activity and exercise

• Limit strenuous activity for at least 4–6 weeks after completing antibiotics or after cardiac surgery, per cardiology advice.
• Gentle walking is encouraged to improve circulation and prevent deconditioning.

Follow‑up care

• Regular echocardiograms (usually at 6 weeks and 6 months) to evaluate valve function.
• Serial blood work to monitor inflammatory markers and drug toxicity (renal, hepatic, hematologic).
• Vaccinations (influenza, pneumococcal, COVID‑19) as recommended, because infections can precipitate relapse.

Psychosocial support

• Seek counseling or support groups for coping with the emotional strain of a serious infection.
• Patients with a history of IV drug use should be linked to addiction services to reduce recurrence risk.

Prevention

Because IE often follows transient bacteremia, preventing those episodes is key.

• Antibiotic prophylaxis – recommended for high‑risk patients (prosthetic valves, previous IE, certain congenital lesions) before dental extractions, periodontal surgery, or upper respiratory tract procedures. Typical regimen: amoxicillin 2 g orally 30‑60 min before the procedure (or clindamycin 600 mg if allergic).<sup>4</sup>
• Maintain excellent oral hygiene; daily brushing and flossing reduce bacterial load.
• Prompt treatment of skin infections, urinary tract infections, and respiratory infections.
• Avoid non‑sterile injections; use sterile techniques if you must inject (e.g., insulin).
• For patients with intravascular devices, follow strict aseptic protocols for line care.

Complications

If untreated or inadequately treated, IE can be fatal. Major complications include:

• Heart failure – caused by valve destruction or severe regurgitation.
• Systemic emboli – vegetations can travel to the brain (stroke), spleen (splenic infarct), kidneys (renal infarction), or extremities (limb ischemia).
• Mycotic aneurysm – infected arterial wall dilation, especially in cerebral vessels; can rupture.
• Abscess formation – within the valve, myocardium, or perivalvular tissue.
• Immune complex phenomena – glomerulonephritis, vasculitis, or arthralgias.
• Septic pulmonary emboli – typical in right‑sided (tricuspid) IE, presenting with cough, hemoptysis, and pleuritic chest pain.
• Mortality – up to 40 % in hospital‑based series; higher in prosthetic‑valve or fungal infections.

When to Seek Emergency Care

References

1. Mayo Clinic. Endocarditis - Symptoms and Causes. Accessed April 2026.
2. World Health Organization. Fact sheet: Infective Endocarditis. 2023.
3. Habib G, et al. 2023 ESC Guidelines for the management of infective endocarditis. European Heart Journal. 2023;44(45):4159‑4240.
4. American Heart Association. 2017 AHA/ACC Guideline for Prevention of Infective Endocarditis. 2017.
5. Cleveland Clinic. Infective Endocarditis. Updated 2024.

```